Biotherapy **6:** 317–320, 1994.

Contents to Volume 6

Volume 6 No. 1

Research articles

Interleukin-2-administration intravenously and intrapleurally in a patient with primary pulmonary adenocarcinoma. Cellular responses in peripheral blood, intrapleural fluid and bronchoalveolar lavage 1
L. Bjermer, H. Grönberg, G. Roos, R. Henriksson

Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study 9
P. Dufour, J.-M. Lang, C. Giron, B. Duclos, P. Haehnel, D. Jaeck, J.-M. Jung, F. Oberling

Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study 13
M. Inoue, Y. Tanaka, N. Sugita, M. Yamasaki, T. Yamanaka, J. Minagawa, K. Nakamuro, T. Tani, Y. Okudaira, T. Karita, K. Takayama, T. Ide, O. Tanizawa

Clinical usefulness of continuous administration of *Nocardia rubra* cell wall skeleton (N – CWS) in diffuse panbronchiolitis (DPB) 19
S. Ishioka, S. Hozawa, K. Hasegawa, T. Saito, M. Takaishi, M. Yamakido

Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2(rIL2): activation by autologous tumour cell alone 25
M. Katano, F. Nagumo, E. Kubota, H. Yamamoto, T. Matsuo, T. Hisatsugu, J. Tadano

The expression and biological activity of IL-2 receptor on a human pancreas cancer cell line 33
H. Kawami, K. Yoshida, Y. Yamaguchi, T. Saeki, T. Toge

The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers 41
K. Satoh, N. Kan, T. Okino, K. Mise, S. Yamasaki, T. Harada, T. Hori, K. Ohgaki, T. Tobe

Restoration of the acute phase response after infection in cyclophosphamide-treated mice by granulocyte colony-stimulating factor 51
M. Sawaki, E. Kita, K. Mikasa, M. Konishi, M. Kumimatsu, S. Kashiba, N. Narita

Cellular interaction against autologous tumorcells between IL-2-cultured lymphocytes and fresh peripheral blood lymphocytes in patients with breast cancer given immuno-chemotherapy 63
S. Yamasaki, N. Kan, K. Mise, T. Harada, Y. Ichinose, Y. Moriguchi, H. Kodama, K. Satoh, K. Ohgaki, T. Tobe

The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients 73
V. Bocci, F. Carraro, M. Zeuli, A. Naldini, F. Calabresi

Instructions to authors 79

Volume 6 No. 2

Research articles

Histological analysis of IL-2 induced regression of murine solid SL2-tumors 83
R.A. Maas, H.F.J. Dullens, D. Henk, J. van Weering, H.J.I. De Mik, J.-W. Koten, R.J. Belger, W. Den Otter

Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice – Validation of virus removal and inactivation 93
B. Trijzelaar

Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy 103
I. Sakita, T. Monden, H. Nagaoka, Y. Katsumoto, T. Wakasugi, N. Tomita, T. Takeda, T. Kobayashi, T. Shimano, T. Mori

Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-*y* (IFN-*y*) in experimental infection with *Listeria monocytogenes* 113
P.M.B. Melissen, W. van Vianen, O. Bidjai, M. van Marion, I.A.J.M. Bakker-Woudenberg

Prevention of doxorubicin-induced caardiotoxicity by recombinant interleukin-1 in hamsters: Doxorubicin cardiotoxicity and interleukin-1 125
T. Yoshida, H. Okumura, H. Kaya, Y. Okabe, S. Matano, S. Ohtake, S. Nakamura, T. Matsuda

Effect of postoperative intrapleural instillations of interleukin-2 in patients with malignant pleurisy due to lung cancer 133
K. Yasumoto, A. Nagashima, H. Nakahashi, T. Ishida, K. Sugimachi, K. Nomoto

The comparative effects of IL-1 and TNF on AMN-anti-Ly 2.1 immunoconjugate therapy 139
K.G. Krauer, G.A. Pietersz

Phase IV group study of natural human interferon alpha (HLBI) on chronic myelogeneous leukaemia 149
S. Arimori, H. Terada, K. Hayami, Y. Aoyagi, S. Motomura, H. Fukawa, N. Akatsuka, S. Shimizu, F. Kodama, S. Chiba, A. Urabe, M. Omine, K. Harada

Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas 155
M. Tsukuda, I. Mochimatsu, M. Sakumoto, S. Furukawa, S. Yuyama, S. Yanoma, A. Kubota

Instructions to authors 163

Volume 6 No. 3

The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes 167
M. Tsukuda, I. Mochimatsu, M. Sakumoto, Y. Mikami, S. Yuyama, S. Yanoma

Locoregional immunotherapy of head and neck cancers utilizing allogenic spleen cells – a report of 2 cases 175
E. Kubota, M. Katano, H. Imamura, H. Kurokawa, T. Katsuki, H. Yamamoto, T. Kisatsugu, F. Nagumo, J. Tadano

Production of granulocyte colony-stimulating factor by head and neck carcinomas 183
M. Tsukuda, T. Nagahara, T. Yago, H. Matsuda, S. Yanoma

Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ 189
J.-T. Chen, K. Hasumi

The detection of a breast cancer antigen on MCF-7 cells reactive with the TCR(α) of a specific killer T cell line 195
F. Okano, H. Tachibana, K. Akiyama, H. Murakami

Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease 205
J. Schüpbach, H. Günthard, M.S.C. Fung, R.-S. Liou, L. Botta, P. Gowland, W. Gordon, D. Gygax, N.T. Chang, T.W. Chang, R. Lüthy, D.G. Praun

A tumor cell line producing granulocyte colony-stimulating factor and an immune supressive factor 217
M. Tsukuda, T. Nagahara, Y. Mikami, T. Yago, H. Matsuda, S. Yanoma

Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2 225
J. Sato, N. Hamaguchi, K. Doken, K. Gotoh, K. Ootsu, S. Iwasa, Y. Ogawa, H. Toguchi

Erratum 233

Instructions to authors 235

Volume 6 No. 4

Research articles

The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-α 239
I. Mochimatsu, M. Tsukuda, S. Furukawa, S. Watanabe, A. Kubota, S. Yanoma

Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunotherapy via the hepatic artery 245
N. Kan, S. Yamasaki, H. Kodama, T. Okino, Y. Ichinose, Y. Moriguchi, L. Li, T. Sugie, M. Imamura

Immunogenicity of recombinant human interleukin-2: Biological features and clinical relevance 251
E.L. Hänninen, J. Knüver-Hopf, J. Atzpodien

***In vivo* anti inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters** 263
V. Barak, D. Peritt, P. Yanai, T. Halperin, A.J. Treves

In vivo anti inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants 271
V. Barak, R. Gorodetsky, J. Weidenfeld, D. Peritt, P. Yanai, T. Halperin, A.J. Treves

Immunoglobulin secreting cells in lymphocytes of patients with IgA deficiency or hyper-IgA 279
N. Kondo, A. Takao, G.P. Li, N. Kuwabara, H. Fujii, T. Orii

Induction of cytolytic activity of lymphocytes from carcinomatous pleural effusion by IL-2 and autologous tumor cells 283
M. Sairenji, S. Yanoma, H. Motohashi, O. Kobayashi, K. Okada, T. Okamoto, M. Tsukuda, M. Umeda

Circumvention of chemotherapy-induced myelosuppression by transfer of the _mdr1_ gene 291
J.J.B. Boesen, K. Nooter, D. Valerio

The induction of murine tumor infiltrating lymphocytes (TIL) by interleukin-2 or T cell growth factor 303
N. Kan, K. Mise, M. Nakanishi, T. Okino, T. Harada, Y. Ichinose, Y. Moriguchi, T. Sugie, L. Li, M. Imamura

Instructions to authors 311